Plain-English translation of NCT06462365 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is the first study in humans testing a new treatment called TRX-103, which uses specially prepared cells to help prevent a serious side effect of stem cell transplants. In patients undergoing transplants for blood cancers, the new cells from a donor's immune system can sometimes attack the patient's body—a condition called graft-versus-host disease. This study will give TRX-103 to patients after their transplant to see if this medication can prevent that dangerous complication from happening.
Graft-versus-host disease is a major problem for patients receiving stem cell transplants and can cause serious, long-lasting damage to the skin, gut, liver, and other organs. Current prevention methods don't work for everyone, so researchers created this medication to offer patients a new way to protect themselves after transplant.
You likely qualify if…
You likely don't qualify if…
After you receive your stem cell transplant, you will be given a single infusion of the new treatment through an IV. The study team will monitor you closely over the following months to watch for any side effects and to track whether you develop graft-versus-host disease. You will need to attend regular visits and may need blood tests and other check-ups as part of the study. The entire enrollment period for the study will run for about 18 to 24 months, with up to 36 patients participating.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States